Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter E Penson

Showing results (21-30 of 100) with videos related to

Pageof 10
Sort By:
Trends in Cardiovascular Medicine|September 24, 2021
Editorial commentary: Bacterial lipopolysaccharide-Stoking the fire of residual risk?Peter E Penson, Neil C Henney
European Journal of Pharmacology|April 6, 2006
Effects of hypoxia on the vasodilator activity of nifedipine and evidence of secondary pharmacological propertiesKenneth J Broadley, Peter E Penson
BMC Medicine|October 9, 2020
LDL-C: lower is better for longer-even at low riskPeter E Penson, Matteo Pirro, Maciej Banach
Current Vascular Pharmacology|December 8, 2022
Which Statin is Best for the Kidneys?Peter E Penson, Maciej Banach, Alice P McCloskey
Current Atherosclerosis Reports|September 1, 2021
RNA Silencing in the Management of DyslipidemiasNeil C Henney, Maciej Banach, Peter E Penson
Exploratory Research in Clinical and Social Pharmacy|June 7, 2024
Patient experiences of their current asthma care and their views toward providing support for patients with asthma in community pharmacy: A Qualitative studyAseel Mahmoud, Rachel Mullen, Peter E Penson, et al.
Pharmacology & Therapeutics|May 25, 2007
Vasopressors for cardiopulmonary resuscitation. Does pharmacological evidence support clinical practice?Peter E Penson, William R Ford, Kenneth J Broadley
Thrombosis and Haemostasis|February 8, 2022
Warfarin-Is Self-Care the Best Care?Leona A Ritchie, Peter E Penson, Deirdre A Lane
Archives of Medical Science : AMS|September 15, 2021
Statins as anti-pyroptotic agentsMasoomeh Khalifeh, Peter E Penson, Maciej Banach, et al.
European Heart Journal|May 14, 2022
Extreme cardiovascular risk-do we need a new risk category?Krzysztof Dyrbuś, Mariusz Gąsior, Peter E Penson, et al.
Pageof 10

Showing results (21-30 of 100) with videos related to

Sort By:
Pageof 10
Trends in Cardiovascular Medicine|September 24, 2021
Editorial commentary: Bacterial lipopolysaccharide-Stoking the fire of residual risk?Peter E Penson, Neil C Henney
European Journal of Pharmacology|April 6, 2006
Effects of hypoxia on the vasodilator activity of nifedipine and evidence of secondary pharmacological propertiesKenneth J Broadley, Peter E Penson
BMC Medicine|October 9, 2020
LDL-C: lower is better for longer-even at low riskPeter E Penson, Matteo Pirro, Maciej Banach
Current Vascular Pharmacology|December 8, 2022
Which Statin is Best for the Kidneys?Peter E Penson, Maciej Banach, Alice P McCloskey
Current Atherosclerosis Reports|September 1, 2021
RNA Silencing in the Management of DyslipidemiasNeil C Henney, Maciej Banach, Peter E Penson
Exploratory Research in Clinical and Social Pharmacy|June 7, 2024
Patient experiences of their current asthma care and their views toward providing support for patients with asthma in community pharmacy: A Qualitative studyAseel Mahmoud, Rachel Mullen, Peter E Penson, et al.
Pharmacology & Therapeutics|May 25, 2007
Vasopressors for cardiopulmonary resuscitation. Does pharmacological evidence support clinical practice?Peter E Penson, William R Ford, Kenneth J Broadley
Thrombosis and Haemostasis|February 8, 2022
Warfarin-Is Self-Care the Best Care?Leona A Ritchie, Peter E Penson, Deirdre A Lane
Archives of Medical Science : AMS|September 15, 2021
Statins as anti-pyroptotic agentsMasoomeh Khalifeh, Peter E Penson, Maciej Banach, et al.
European Heart Journal|May 14, 2022
Extreme cardiovascular risk-do we need a new risk category?Krzysztof Dyrbuś, Mariusz Gąsior, Peter E Penson, et al.
Pageof 10